Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04302025 · ClinicalTrials.gov registry record · Phase 2

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Genentech.

Recruiting
Registry status
Phase 2
Development phase
99
Enrollment target
20
Study locations

NCT04302025: Recruiting Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Genentech.

NCT04302025 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Genentech. The registered enrollment target is 99 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04302025, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Genentech.

RECRUITING
Registry status
Phase 2
Development phase
99 participants
Enrollment target
20
Study locations

Study Summary

This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

Primary Outcome

MPR is defined as ≤ 10% residual viable tumor cells as scored by local pathologists.

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG Vemurafenib
  • DRUG Alectinib
  • DRUG Entrectinib
  • DRUG Cobimetinib
  • DRUG Pralsetinib

Study Locations (20)

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • City of Hope - Orange County Lennar Foundation Cancer Center - Irvine
  • USC Norris Cancer Center - Los Angeles
  • Cedars-Sinai Medical Center - Los Angeles
  • University of California Los Angeles - Jonsson Comprehensive Cancer Center - Los Angeles
  • The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange - Orange
  • UC Davis Comprehensive Cancer Center - Sacramento
  • UCSF Helen Diller Family CCC - San Francisco

Illinois

  • Northwestern University - Chicago
  • Northwestern Medicine Cancer Center Kishwaukee - DeKalb
  • Northwestern Medicine Cancer Center Delnor - Geneva
  • Northwestern Medicine Cancer Center Warrenville - Warrenville

Massachusetts

  • Boston Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

Michigan

  • University of Michigan - Ann Arbor
  • Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center - Farmington Hills

Colorado

  • University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center) - Aurora

Connecticut

  • Yale Cancer Center - New Haven

District of Columbia

  • MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center) - Washington D.C.

Florida

  • Moffitt Cancer Center - Tampa

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2020-11-06
Est. Completion 2030-05-30
Phase Phase 2
Genentech

332 total trials

What NCT04302025 shows while recruiting

NCT04302025 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Vemurafenib is the first listed.

NCT04302025 names 20 study sites across 8 states, led by California, Illinois, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04302025 about?

NCT04302025 is a clinical study titled "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)". This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

What is the current status of trial NCT04302025?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2020-11-06. Estimated completion is 2030-05-30.

What conditions does trial NCT04302025 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT04302025?

The interventions under investigation include: Vemurafenib (DRUG), Alectinib (DRUG), Entrectinib (DRUG), Cobimetinib (DRUG), Pralsetinib (DRUG).

Who is sponsoring clinical trial NCT04302025?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04302025 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04302025's enrollment target sits among peer trials

99 244th of 454 higher than 210 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03965234 · 99 participants · Phase 1

    Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

  • NCT04022616 · 99 participants

    Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

  • NCT04042844 · 99 participants · Phase 2

    A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

  • NCT04143724 · 99 participants · Phase 2

    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04302025

Source: ClinicalTrials.gov NCT04302025, the US trial registry maintained by the National Library of Medicine. NCT04302025 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.